Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01359917|
Recruitment Status : Completed
First Posted : May 25, 2011
Last Update Posted : June 13, 2011
The hypotheses of this study were that:
- HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression.
- Treatment of HIV lipodystrophy using autologous fat transfer, polylactic acid or Bio-alcamid, is associated with an improvement in psychological morbidity and anatomical volume of treated areas.
- The DI3D system is a valid and reproducible method of recording and measuring facial 3-D volume.
|Condition or disease|
|HIV-Associated Lipodystrophy Syndrome|
|Study Type :||Observational|
|Actual Enrollment :||50 participants|
|Observational Model:||Case Control|
|Official Title:||Psychological Morbidity and Facial Volume in HIV Lipodystrophy:|
|Study Start Date :||August 2006|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
autologous fat transfer
patients received fat transfer for HIV lipodystrophy
treatment with polylactic acid (PLA) for HIV lipodystrophy
- measurement of 3-D facial volume [ Time Frame: 2 years ]3-D facial camera
- psychological outcome [ Time Frame: 2 years ]derriford appearance scale hospital anxiety and depression scale
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01359917
|Principal Investigator:||Kenneth J Stewart, FRCSPlast||NHS Lothian|